Scarica l'app Stockscreener
24.65
0.28%
0.07
Dopo l'orario di chiusura:
24.63
-0.02
-0.08%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$24.58
Aprire:
$24.655
Volume 24 ore:
34.39M
Relative Volume:
0.82
Capitalizzazione di mercato:
$140.15B
Reddito:
$63.83B
Utile/perdita netta:
$10.75B
Rapporto P/E:
13.11
EPS:
1.88
Flusso di cassa netto:
$12.44B
1 W Prestazione:
-0.40%
1M Prestazione:
-3.90%
6M Prestazione:
-3.22%
1 anno Prestazione:
-13.36%
Intervallo 1D:
$24.47
$24.77
Intervallo di 1 settimana:
$23.86
$24.92
Portata 52W:
$20.91
$30.43
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Confronta PFE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.65 | 139.75B | 63.83B | 10.75B | 12.44B | 1.88 |
|
LLY
Lilly Eli Co
|
639.43 | 569.45B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
172.78 | 418.62B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
198.64 | 350.91B | 58.33B | 3.76B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
119.31 | 229.50B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
80.30 | 199.90B | 63.62B | 16.41B | 14.72B | 6.49 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
[Latest] US Personalized Medicine Market Size/Share Worth USD 252.93 Billion by 2034 at a 17.32% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Pfizer Stock Surges on Revised Earnings Guidance as $850M Trading Volume Ranks 117th Amid Valuation Discount to Peers - AInvest
Pfizer/BioNTech may not win FDA renewal for pediatric COVID shot: report - MSN
Pfizer/Astellas’s Padcev Scores First Big Win In Bladder Cancer Study - insights.citeline.com
Pfizer (PFE) Reports Positive Phase 3 Results In Bladder Cancer Treatment Study - simplywall.st
Pfizer Raises Its Guidance and Analysts Up Their TargetsPFE Stock Looks Cheap - Yahoo Finance
The Zacks Analyst Blog Highlights Pfizer, Novo Nordisk and Eli Lilly - The Globe and Mail
Pfizer looks to expand ADC use after positive bladder cancer data - BioPharma Dive
Pfizer’s Gene Therapy Study for Duchenne Muscular Dystrophy: Key Insights for Investors - TipRanks
Pfizer and Astellas Pharma’s Prostate Cancer Study: A Potential Game-Changer? - TipRanks
Pfizer’s Abrocitinib Study: A Potential Game-Changer for Atopic Dermatitis Treatment - TipRanks
Pfizer’s MagnetisMM-4 Study: A New Hope for Multiple Myeloma Treatment - TipRanks
Pfizer In Spotlight As FDA Reportedly Mulls Withdrawing Authorization For COVID-19 Vaccine For Kids Under 5 - Stocktwits
What's Going On With Merck Stock Tuesday?Merck & Co (NYSE:MRK), Pfizer (NYSE:PFE) - Benzinga
BlinkRx’s Ties to Donald Trump Jr. Questioned Amid Pfizer and Elicio Therapeutics’ Cancer Research Updates - geneonline.com
Former Pfizer Chief Scientific Officer joins MC Sciences as Independent Chairman - Morningstar
Implications of Potential Pfizer Pediatric Vaccine Withdrawal on the U.S. Immunization Market - AInvest
Ascites Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | PharmaIN, AstraZeneca plc, Pfizer Inc., Novartis AG, Baxter International Inc., Becton, Dickinson and Company - The Globe and Mail
Pfizer's combination therapy improves survival in bladder cancer trial - Reuters
Solid Earnings Reflect Pfizer's (NYSE:PFE) Strength As A Business - simplywall.st
Statutory Profit Doesn't Reflect How Good Pfizer's (NYSE:PFE) Earnings Are - Yahoo Finance
FDA Weighs Pulling Pfizer’s Covid Vaccine for Kids Under Age 5 - Bloomberg.com
Pfizer’s combination therapy improves survival in bladder cancer trial - PharmaLive
Pfizer, Astellas post late-stage trial win for Padcev with Merck’s Keytruda in bladder cancer - Seeking Alpha
Pfizer and Merck's Bladder Cancer Breakthrough: A Paradigm Shift in Oncology and a Win for Shareholders? - AInvest
Pfizer-Astellas bladder cancer therapy shows survival benefits in trial By Investing.com - Investing.com South Africa
Pfizer and Astellas Announce Breakthrough in Bladder Cancer Treatment - TipRanks
Pfizer drug extends survival for some bladder cancer patients | STAT - statnews.com
Pfizer’s Padcev Plus Keytruda Extends Bladder Cancer Survival - Bloomberg.com
Eli Lilly, Pfizer Seek Spot in China Private Insurance Catalog - Bloomberg.com
Pfizer Just Beat Its Earning Estimates. Is This the Beginning of a Turnaround for the Pharmaceutical Stock? - Yahoo Finance
If You'd Invested $1,000 in Pfizer (PFE) Stock 3 Years Ago, Here's How Much You'd Have Today - Yahoo Finance
Pfizer Reports Positive Topline Phase 3 Results For HYMPAVZI™ In Hemophilia A or B With Inhibitors - Insider Monkey
Astrocytoma Market to See Strong Growth Through 2034 as Pfizer, - openPR.com
Pfizer Raises Its Guidance And Analysts Up Their TargetsPFE Stock Looks Cheap - Barchart.com
Pfizer workers taken to hospital for 'potential exposure to materials,' company says - WWMT
FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply - Benzinga
Sponsored Content: Pfizer’s Anti-Counterfeit Lab - WTNH.com
Pfizer’s New Study on Zavicefta: A Potential Game-Changer for Sepsis and Renal Impairment - TipRanks
Pfizer’s Gene Therapy Study for Duchenne Muscular Dystrophy: Key Update for Investors - TipRanks
Flu Shot Season Puts Pfizer Back In Radio’s Ad Elite - Radio Ink
Pfizer launches next-gen vaccine for pneumococcal disease - The Economic Times
Should Pfizer Stock Be in Your Portfolio After Solid Q2 Results? - The Globe and Mail
Should Pfizer Stock Be In Your Portfolio After Solid Q2 Results? - Barchart.com
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
FDA gives Arvinas and Pfizer’s vepdegestrant NDA for breast cancer - Yahoo Finance
Pfizer Inc. - Britannica
Precision Trading with Pfizer Inc. (PFE) Risk Zones - news.stocktradersdaily.com
How Pfizer Inc. (PFE) Affects Rotational Strategy Timing - news.stocktradersdaily.com
FDA Accepts Pfizer (PFE) Vepdegestrant NDA for Breast Cancer, Fast Track Designation Awarded - simplywall.st
GlaxoSmithKline Will Get $500M In CureVac-Pfizer Patent Deal - Law360
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.37%
1.78%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):